 CRANBURY, N.J., May 4, 2021 PRNewswire -- Palatin Technologies, Inc. NYSE American: PTN, a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced that the United States Patent and Trademark Office USPTO issued Notices of Final Determination and Requirement for Election on a patent term extension for two U.S. patents covering the Vyleesi bremelanotide injection drug substance, U.S. patents 6,579,968 and 6,794,489. 